Table 1.
Specificity of targeting of IGF-1R in vivo
| 1 µg | 40 µg | |
|---|---|---|
| Blood | 0.14 ± 0.01* | 0.22 ± 0.04 |
| Lung | 1.19 ± 0.06* | 0.61 ± 0.05 |
| Liver | 4.08 ± 0.1 | 2.85 ± 1.3 |
| Spleen | 3 ± 0.6 | 3.13 ± 2.4 |
| Pancreas | 0.98 ± 0.1* | 0.33 ± 0.06 |
| Stomach | 1.04 ± 0.3* | 0.48 ± 0.05 |
| Colon | 1.5 ± 0.4* | 0.7 ± 0.4 |
| Kidney | 7.5 ± 0.7 | 6.4 ± 0.5 |
| Salivary gland | 1.6 ± 0.1* | 1.0 ± 0.1 |
| Tumor | 0.9 ± 0.1* | 0.5 ± 0.1 |
| Muscle | 0.27 ± 0.01 | 0.26 ± 0.1 |
| Bone | 0.63 ± 0.1 | 0.43 ± 0.1 |
Biodistribution (4 h after injection) of 99mTc-ZIGF1R:4551-GGGC in Balb/c nu/nu mice bearing IGR-1R-expressing DU-145 prostate cancer xenografts injected with 1 or 40 μg protein. Uptake of 99mTc-ZIGF1R:4551-GGGC in tumors and IGF-1R-expressing organs (lung, pancreas, stomach, and colon) was significantly lower in animals injected with higher dose of ZIGF1R:4551-GGGC
The data are expressed as %IA/g and represent the average value from 4 animals ± standard deviation
* Significant difference (p < 0.05) in uptake between mice injected with 1 and 40 μg protein